Results 191 to 200 of about 4,488 (204)
Some of the next articles are maybe not open access.
3H-Spiperone binding to peripheral mononuclear cells in psychiatric in-patients
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 19961. There is an ongoing controversy, if increased binding of 3H-spiperone to lymphocytes might discriminate between schizophrenia and other psychiatric diseases or even be a genetic vulnerability marker for schizophrenia, or predict the response to neuroleptic treatment. 2.
Jürgen Fritze +2 more
openaire +3 more sources
Hyperprolactinaemia does not alter specific striatal 3H-spiperone binding in the rat
Biochemical Pharmacology, 1986We have investigated the effect of single injections (1 mg/animal i.v.) of prolactin or vehicle, and repeated depot (0.125-1.0 mg/animal/day) or bolus (1.0 mg/animal/day) administration of prolactin or vehicle for 6 days to adult male rats. The density (Bmax) and affinity (Kd) of specific striatal [3H]spiperone binding was not changed by any of the ...
Peter Jenner +2 more
openaire +3 more sources
Alzheimer'S disease: Monoamines and spiperone binding reduced in nucleus basalis
Annals of Neurology, 1986AbstractLevels of dopamine and serotonin, and of their precursors and metabolites, were measured in the nucleus basalis of Meynert (nbM) of patients with Alzheimer's disease and control patients. [3H]Spiperone binding to membrane homogenates of the nbM, indicative of both dopaminergic and serotonergic receptors, was also measured. The nbM from patients
D L Sparks +2 more
openaire +3 more sources
Binding of 3H-spiperone to human lymphocytes: A biological marker in schizophrenia?
Psychiatry Research, 1985The specific binding of the dopamine antagonist 3H-spiperone to lymphocytes from a healthy control group (n = 40), a group of acute, unmedicated schizophrenic patients (n = 27), and a psychiatric control group (n = 16) was investigated. There were no differences in binding parameters between the healthy controls (Bmax 2.6 +/- 0.7 fmoles/10(6) cells; Kd
Manfred Ackenheil +3 more
openaire +3 more sources
3H-spiperone binding capacity in mononuclear cells: A family study
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 19931. A family study was carried out using a putative biological vulnerability trait in families of schizophrenics and schizoaffective indexprobands to investigate, if the clinical phenotype and a biological marker for schizophrenia are cosegregating within families. 2.
Heiner Sauer +7 more
openaire +3 more sources
Synthesis of no-carrier-added N-([18F]fluoroalkyl)spiperone derivatives
International Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes, 19863-N-([18F]fluoroalkyl)spiperone derivatives (2,3) can be prepared by N-alkylation of spiperone (1) with fluoroalkyl halides. The fluoroalkylating species 2-[18F]fluoroethyl bromide (7), 3-[18F]fluoropropyl bromide (8) and 4-[18F]fluorobutyl bromide (9) were prepared by [18F]fluoride ion displacement of the corresponding trifluoromethanesulfonates ...
John A. Katzenellenbogen +4 more
openaire +3 more sources
Ketanserin and Spiperone as Templates for Novel Serotonin 5-HT2A Antagonists
Current Topics in Medicinal Chemistry, 2002The structures of ketanserin (1) and spiperone (2) were examined in detail to determine the role of various substituent groups on 5-HT(2A) receptor affinity and selectivity. It was found that the presence of the quinazoline ring of ketanserin detracts from selectivity and that various ring-opened analogs displayed ketanserin-like affinity and up to 30 ...
Milt Teitler +7 more
openaire +3 more sources
Estrogen increases both spiperone-induced catalepsy and brain levels of [3H]spiperone in the rat
Brain Research, 1979Charles F. Saller +2 more
openaire +3 more sources
Why does 4′‐nitro‐spiperone fail as precursor for the preparation of [F‐18]‐spiperone?
Journal of Labelled Compounds and Radiopharmaceuticals, 1989W. Vanryckeghem, M. Gvsemans, J. Mertens
openaire +2 more sources
Spiperone-labelled dopamine transporter in lymphocytes
European Neuropsychopharmacology, 1992Brigitta Bondy +3 more
openaire +2 more sources